Personalized medicine in interstitial lung diseases
作者： Paolo Spagnolo , Justin M. Oldham , Mark G. Jones , Joyce S. Lee
DOI: 10.1097/MCP.0000000000000370
关键词: Personalized medicine 、 Medicine 、 Lung 、 Hypersensitivity pneumonitis 、 Interstitial lung disease 、 Precision medicine 、 Idiopathic interstitial pneumonia 、 Idiopathic pulmonary fibrosis 、 Pathology 、 Sarcoidosis 、 Pulmonary and Respiratory Medicine
摘要: Purpose of reviewA number recent studies have explored the possibility to apply personalized medicine interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), most common and deadly pneumonias. In our review, we summarize discu
elsevier.com
lww.com
sci-hub.se 参考文章(65)
Stella Alexiou-Daniel, Despina Papakosta, Katerina Manika, Dimitrios Patakas, Antonis Antoniadis, Anna Papa, Theodore Kontakiotis, Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases. ,vol. 24, pp. 134- 140 ,(2007)
Martin Petrek, Personalized medicine in sarcoidosis Current Opinion in Pulmonary Medicine. ,vol. 21, pp. 532- 537 ,(2015) , 10.1097/MCP.0000000000000194
Monica Arnedos, Cecile Vicier, Sherene Loi, Celine Lefebvre, Stefan Michiels, Herve Bonnefoi, Fabrice Andre, Precision medicine for metastatic breast cancer—limitations and solutions Nature Reviews Clinical Oncology. ,vol. 12, pp. 693- 704 ,(2015) , 10.1038/NRCLINONC.2015.123
Evans R. Fernández Pérez, Craig E. Daniels, Jennifer St. Sauver, Thomas E. Hartman, Brian J. Bartholmai, Eunhee S. Yi, Jay H. Ryu, Darrell R. Schroeder, Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis Chest. ,vol. 137, pp. 129- 137 ,(2010) , 10.1378/CHEST.09-1002
, Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. The New England Journal of Medicine. ,vol. 370, pp. 2093- 2101 ,(2014) , 10.1056/NEJMOA1401739
Brett M. Elicker, Kirk D. Jones, Travis S. Henry, Harold R. Collard, Multidisciplinary Approach to Hypersensitivity Pneumonitis. Journal of Thoracic Imaging. ,vol. 31, pp. 92- 103 ,(2016) , 10.1097/RTI.0000000000000186
Robert P Baughman, Jan C Grutters, New treatment strategies for pulmonary sarcoidosis : antimetabolites, biological drugs, and other treatment approaches The Lancet Respiratory Medicine. ,vol. 3, pp. 813- 822 ,(2015) , 10.1016/S2213-2600(15)00199-X
Daina B. Esposito, Stephan Lanes, Macarius Donneyong, Crystal N. Holick, Joseph A. Lasky, David Lederer, Steven D. Nathan, Sean O’Quinn, Joseph Parker, Trung N. Tran, Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. American Journal of Respiratory and Critical Care Medicine. ,vol. 192, pp. 1200- 1207 ,(2015) , 10.1164/RCCM.201504-0818OC
Justin M. Oldham, Shwu-Fan Ma, Fernando J. Martinez, Kevin J. Anstrom, Ganesh Raghu, David A. Schwartz, Eleanor Valenzi, Leah Witt, Cathryn Lee, Rekha Vij, Yong Huang, Mary E. Strek, Imre Noth, TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis American Journal of Respiratory and Critical Care Medicine. ,vol. 192, pp. 1475- 1482 ,(2015) , 10.1164/RCCM.201505-1010OC
S. Gavini, R. T. Finn, W.-K. Lo, H. J. Goldberg, R. Burakoff, N. Feldman, W. W. Chan, Idiopathic pulmonary fibrosis is associated with increased impedance measures of reflux compared to non-fibrotic disease among pre-lung transplant patients Neurogastroenterology and Motility. ,vol. 27, pp. 1326- 1332 ,(2015) , 10.1111/NMO.12627